High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells.

Bone Marrow Transplant · 2001 · PMC7091626 · PMID 11781645

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

of borderline significanceP = 0.05actually significant

The lower value of CD3 + cells at 3 months for the PBPC group was of borderline significance compared to the controls ( P = 0.05).

also in 2,624 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.